Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

[1]  Yoshiyuki Suzuki,et al.  Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. , 2008, Journal of hepatology.

[2]  N. Hayashi,et al.  Early emergence of entecavir‐resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  F. Zoulim,et al.  Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. , 2008, Journal of hepatology.

[4]  Y. Imai,et al.  Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine , 2008, Hepatology Research.

[5]  P. Lampertico,et al.  Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.

[6]  N. Hayashi,et al.  Type B Fulminant Hepatitis Is Closely Associated with a Highly Mutated Hepatitis B Virus Strain , 2007, Intervirology.

[7]  M. Buti,et al.  Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. , 2007, Journal of hepatology.

[8]  Yoshiyuki Suzuki,et al.  Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine , 2007, Journal of Gastroenterology.

[9]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.

[10]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[11]  Sheng-Nan Lu,et al.  Virological Response and Incidence of Adefovir Resistance in Lamivudine-Resistant Patients Treated with Adefovir Dipivoxil , 2005, Antiviral therapy.

[12]  H. Lee,et al.  Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.

[13]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[14]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[15]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[16]  J. Tsai,et al.  Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan , 2004, Journal of Clinical Pathology.

[17]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[18]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[19]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[21]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[22]  M. Sata,et al.  Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. , 2001, Journal of hepatology.

[23]  F. Mahoney,et al.  Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection , 1999, Clinical Microbiology Reviews.

[24]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[25]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .